Cullinan Therapeutics, Inc. (CGEM): who owns it and who trades it
As of Nov 16, 2026, CGEM insiders reported 27 open-market sales worth $2.5M and no purchases in the last 12 months, with 2% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Michaelson (Chief Scientific Officer), with $1.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cullinan Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CGEM
184 funds and institutions reported CGEM shares worth $1.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Mpm Bioimpact LLC with 15.8%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Mpm Bioimpact LLC | 9.73M | 15.83% | $177M | +27% |
| Lynx1 Capital Management LP | 8.96M | 14.58% | $163M | No change |
| Bvf Inc | 5.75M | 9.36% | $105M | No change |
| BlackRock, Inc. | 5.23M | 8.51% | $95.3M | +18% |
| T. Rowe Price Associates | 3.83M | 6.23% | $69.7M | +88% |
| State Street Corp | 3.67M | 5.97% | $66.8M | +44% |
| Kynam Capital Management, LP | 3.11M | 5.07% | $56.7M | No change |
| Vanguard Capital Management LLC | 2.61M | 4.25% | $47.6M | +5% |
| Rtw Investments, LP | 2.36M | 3.85% | $43.1M | +39% |
| Siren, L.L.C. | 1.89M | 3.08% | $34.5M | +59% |
| Geode Capital Management, LLC | 1.55M | 2.52% | $28.2M | +13% |
| Blue Owl Capital Holdings LP | 1.54M | 2.51% | $28M | -19% |
| Venrock Adviser, LLC | 1.38M | 2.25% | $25.1M | No change |
| Boothbay Fund Management, LLC | 1.08M | 1.76% | $19.7M | -3% |
| Dimensional Fund Advisors LP | 1.05M | 1.70% | $19.1M | +16% |
| Goldman Sachs Group Inc | 1.00M | 1.63% | $18.2M | +120% |
| Affinity Asset Advisors, LLC | 875,760 | 1.42% | $15.9M | +12% |
| Vanguard Portfolio Management LLC | 738,741 | 1.20% | $13.5M | +34% |
| Boone Capital Management LLC | 704,442 | 1.15% | $12.8M | – |
| Elmind Capital, LP | 690,000 | 1.12% | $12.6M | +30% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CGEM insiders reported $0 of open-market purchases and $2.5M of sales. 2% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale plan | 4,000 | $12.36 | $49.4K | Form 4 |
| Sep 8, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8,000 | $21.57 | $173K | Form 4 |
| Aug 13, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 30,000 | $20.26 | $608K | Form 4 |
| Jul 6, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8,000 | $17.82 | $143K | Form 4 |
| May 5, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 200 | $15.58 | $3.1K | Form 4 |
| May 5, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 7,800 | $14.60 | $114K | Form 4 |
| Mar 5, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8,000 | $15.68 | $125K | Form 4 |
| Feb 25, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 1,780 | $14.14 | $25.2K | Form 4 |
| Feb 24, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 3,601 | $14.47 | $52.1K | Form 4 |
| Feb 24, 2026 | Nadim Ahmed | CEO | Sale | 13,515 | $14.47 | $196K | Form 4 |
| Feb 24, 2026 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 4,582 | $14.47 | $66.3K | Form 4 |
| Feb 23, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 1,752 | $13.99 | $24.5K | Form 4 |
| Feb 20, 2026 | Mary Kay Fenton | CFO | Sale | 4,398 | $13.62 | $59.9K | Form 4 |
| Feb 20, 2026 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 4,982 | $13.62 | $67.9K | Form 4 |
| Feb 20, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8,000 | $14.30 | $114K | Form 4 |
| Feb 20, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 3,742 | $13.62 | $51K | Form 4 |
| Feb 20, 2026 | Nadim Ahmed | CEO | Sale | 16,381 | $13.62 | $223K | Form 4 |
| Feb 12, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 416 | $12.03 | $5K | Form 4 |
| Jan 22, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 4,000 | $12.30 | $49.2K | Form 4 |
| Dec 23, 2025 | Nadim Ahmed | CEO | Sale | 9,922 | $10.01 | $99.3K | Form 4 |
| Dec 19, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 1,345 | $10.01 | $13.5K | Form 4 |
| Dec 18, 2025 | Jacquelyn L Sumer | Chief Legal Officer | Sale | 3,480 | $9.67 | $33.7K | Form 4 |
| Dec 18, 2025 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 4,632 | $9.67 | $44.8K | Form 4 |
| Dec 18, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 2,898 | $9.67 | $28K | Form 4 |
| Dec 15, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 995 | $11.90 | $11.8K | Form 4 |
| Dec 12, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 2,148 | $12.38 | $26.6K | Form 4 |
| Nov 24, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 4,000 | $12.30 | $49.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jennifer Michaelson | Chief Scientific Officer | – | $1.7M | Nov 5, 2026 |
| Nadim Ahmed | President and CEO, Director | – | $518K | Feb 24, 2026 |
| Jeffrey Alan Jones | Chief Medical Officer | – | $179K | Feb 24, 2026 |
| Mary Kay Fenton | Chief Financial Officer | – | $59.9K | Feb 20, 2026 |
| Jacquelyn L Sumer | Chief Legal Officer | – | $33.7K | Dec 18, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CGEM short interest
High short interest. 12.3% of CGEM shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 9%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.93M CGEM shares were sold short, 12.3% of the shares outstanding, up 3.8% from the report before. At the average daily volume of 594,711 shares, buying them all back would take about 13.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.93M | 12.32% | +4% | 594,711 | 13.3 |
| Oct 15, 2026 | 7.64M | 11.87% | +0% | 930,539 | 8.2 |
| Sep 30, 2026 | 7.63M | 11.86% | -21% | 1.51M | 5.1 |
| Sep 15, 2026 | 9.63M | 14.96% | -7% | 884,954 | 10.9 |
| Aug 31, 2026 | 10.37M | 16.12% | -2% | 669,836 | 15.5 |
| Aug 14, 2026 | 10.59M | 16.45% | +3% | 685,400 | 15.4 |
| Jul 31, 2026 | 10.25M | 15.93% | -0% | 534,845 | 19.2 |
| Jul 15, 2026 | 10.29M | 16.74% | -3% | 675,823 | 15.2 |
| Jun 30, 2026 | 10.60M | 17.24% | +29% | 1.60M | 6.6 |
| Jun 15, 2026 | 8.19M | 13.32% | +3% | 1.30M | 6.3 |
| May 29, 2026 | 7.97M | 12.97% | -8% | 1.13M | 7.0 |
| May 15, 2026 | 8.68M | 14.12% | -1% | 1.06M | 8.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cullinan Therapeutics company events
Cullinan Therapeutics filed 17 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Nov 9, 2026AnnouncementClinical data was presented from the ongoing Phase 1b/2a clinical trial in velinotamig in patients with active, refractory, moderate-to-severe SLE being conducted by Genrix in China at the American College of Rheumatology Convergence 2026. Filing
- Nov 4, 2026AnnouncementThe Company shared updated data from its Phase 1 dose escalation clinical trial for CLN-049 in patients with relapsed or refractory AML or MDS. As of the data cutoff, 87 patients (76 AML, 11 MDS) were enrolled across 13 cohorts (target dose range, 1.5-24 µg/kg). Filing
- Oct 2, 2026AnnouncementThe Company announced the initiation of a NDA submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations under the FDA’s RTOR program. Filing
- Sep 24, 2026AnnouncementThe Company outlined its plans to share the following immunology and oncology pipeline updates in the fourth quarter of 2026. Filing
- Sep 14, 2026AnnouncementThe Company, together with Taiho, announced results from the Phase 3 REZILIENT3 clinical trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with EGFR ex20ins NSCLC. After a safety lead-in (n=6), a total of 279 advanced NSCLC patients… Filing
- Aug 13, 2026AnnouncementThe Company and Taiho announced that the REZILIENT3 clinical trial met its primary endpoint of PFS at a planned interim analysis. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- Jun 10, 2026AnnouncementThe Company shared updated clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA and in patients with treatment-refractory moderate to severe SLE. Filing
- Jun 8, 2026AnnouncementThe Company shared initial clinical data from its Phase 1 OUTRACE clinical trials for CLN-978 in patients with treatment-refractory RA and in patients with treatment-refractory moderate to severe SLE. Filing
- May 18, 2026AnnouncementThe Company announced initial clinical data from its Phase 1 OUTRACE Program for CLN-978 in patients with treatment-refractory RA and in patients with treatment-refractory moderate to severe SLE. As of a January 14, 2026 cutoff date, 14 patients were dosed across the RA (cohorts 1-3, n=5) and SLE… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Jan 8, 2026AnnouncementThe Company provided an update on the anticipated program milestones for 2026 as set out below. Filing
- Dec 8, 2025AnnouncementThe Company presented updated clinical data from its Phase 1 study of CLN-049 in patients with r/r AML and MDS at the ASH Annual Meeting. Filing
- Nov 21, 2025AgreementEnded an important agreement. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cullinan Therapeutics financials
Famous investors that hold CGEM
5 of the 50 well-known investors we track reported holding CGEM in their latest 13F filing. The largest position is Ken Fisher's, worth $12.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 800,961 | $12.3M | 0.0% | +2125% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 290,011 | $4.5M | 0.0% | -11% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 52,838 | $811K | 0.0% | -87% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 32,176 | $494K | 0.0% | +43% |
| Israel Englander · Millennium Management | Q3 2026 | 25,633 | $393K | 0.0% | -93% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CGEM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.0% |
Questions about Cullinan Therapeutics, Inc. (CGEM) stock
Who owns the most CGEM stock?
The largest reported owner of Cullinan Therapeutics, Inc. (CGEM) is Mpm Bioimpact LLC, with 15.8% of the company. In total, 184 funds and institutions reported holding CGEM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CGEM insiders buying or selling?
In the last 12 months, CGEM insiders reported no open-market purchases and 27 sales worth $2.5M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in CGEM?
As of Oct 30, 2026, 7.93M CGEM shares were sold short, 12.3% of the shares outstanding, up 3.8% from the report before. At the average daily volume of 594,711 shares, buying them all back would take about 13.3 trading days (days to cover). See the history.
Which famous investors hold CGEM?
5 of the 50 well-known investors we track reported CGEM in their latest 13F filing, including Ken Fisher, Jim Simons, Ken Griffin. The largest position is worth $12.3M. See all holders.
Executive pay
Cullinan Therapeutics's chief executive was paid a total of $5.1M for the year ended Dec 31, 2025, down 34% from $7.7M the year before. In the last 12 months, Cullinan Therapeutics's executives and directors bought no stock on the open market and sold $2.5M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.